Haisco Pharmaceutical Expects to Double H1 Profit on Product Growth, Subsidies; Shares Up 4%

Haisco Pharmaceutical Group (SHE:002653) expected to double its first-half profit due to rapid product growth and government subsidies.H1 net profit attributable to shareholders is expected to range

MT NewswiresJul 12 02:12 ET

Haisco Pharmaceutical Group: 2024 Interim Performance Forecast

Sensex a shareJul 11 12:00 ET · Announcements

Haisco Pharmaceutical Group Gets China Nod for Diabetic Neuropathy Tablets

China's medical products administrator granted Haisco Pharmaceutical Group (SHE:002653) a drug registration certificate for its clegambalin besylate capsules, according to a Monday filing with the She

MT NewswiresJul 8 08:52 ET

Here's Why Haisco Pharmaceutical Group (SZSE:002653) Can Manage Its Debt Responsibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor

Simply Wall StJun 29 21:31 ET

Haisco Pharmaceutical Gets Nod to Trial Tumor Drug; Shares Up 3%

Haisco Pharmaceutical Group (SHE:002653) will conduct clinical trials on its HSK42360 tablets after receiving approval from China's National Medical Products Administration, the company said in its fi

MT NewswiresJun 12 23:33 ET

Haisco Pharmaceutical Group (002653.SZ): Innovative drug HSK42360 tablets approved for clinical trials.

On June 12th, Gelunhui reported that Haisco Pharmaceutical Group (002653.SZ), a subsidiary of the company, recently received the Drug Clinical Trial Approval Notice issued by the National Drug Administration for HSK42360 tablets. HSK42360 is a small-molecule inhibitor that targets BRAFV600 mutations and has brain permeability, which was independently developed by the company. It is clinically intended for the treatment of advanced solid tumors with BRAFV600 mutations. Pre-clinical research results have shown that HSK42360 exhibits excellent anti-tumor effects in multiple BRAFV600 mutation solid tumor efficacy models.

Gelonghui FinanceJun 12 04:20 ET